Introduction
Breast cancer is the most prevalent cancer in women.
1 Treatment with anthracycline-based chemotherapy has significantly improved disease-free and overall survival in moderate and high-risk breast cancer patients. 2 long-term side effects from oncologic agents are clinically important. Anthracycline-based chemotherapy has been associated with a dose-dependent risk of development of heart failure (HF) in early observational and pathophysiological studies; 5 however, since development of HF may be delayed several years after exposure to treatment, 6 a substantial under-reporting could be expected, in studies without extended follow-up. The risk of late-onset HF, more than 1 year after treatment, is therefore mainly based on observational studies. 7 A potential increased risk of HF is, however, important since it is associated with considerable increased burden of morbidity, an increased risk of mortality and a reduced quality of life. 8, 9 The aim of this study was to evaluate the effect of anthracycline-based chemotherapy on long-term risk of clinical HF compared with non-anthracycline-based chemotherapy in women with early stage breast cancer treated in a randomized controlled trial.
Methods

Study population
This study is a post hoc analysis of data from the Danish Breast Cancer Cooperative Group (DBCG) 89D randomized controlled 2 Between December 1989 and May 1998, the DBCG 89D trial assigned 1224 Nordic mainly Caucasian patients to nine cycles of either cyclophosphamide 600 mg/m 2 , epirubicin 60 mg/m 2 and 5-fluorouracil 600 mg/m 2 (CEF) or cyclophosphamide 600 mg/m 2 , methotrexate 40 mg/m 2 and 5-fluorouracil 600 mg/m 2 (CMF) after radical resection of early unilateral breast cancer. The primary result of the trial favoured the epirubicin-containing regime with improvement of both primary outcomes, which were disease-free and overall survival. Evaluation of left ventricular ejection fraction was not part of the original protocol, but clinical cardiac events were recorded. 2 A total of 962 Danish participants from the trial were included in this study, since access to follow-up data on patients from other Nordic countries was not achievable. Patients with a diagnosis of HF before the diagnosis of breast cancer were excluded from the analyses.
Endpoint and follow-up
The primary study endpoint was a diagnosis of HF defined by the following International Classification of Diseases (ICD)-10 codes: DI50-50.9, DI42-42.9, DI11.0, DI13.0, DI13.2, and ICD-8 codes: 427.0 and 427.1. Patients with only emergency visits or outpatients seen on one occasion with no further follow-up of chronic HF were excluded from the analyses. Patients were followed from trial inclusion to the first occurrence of the primary endpoint, a competing event of death, a censoring event of emigration or end of study period (follow-up period ended by 31 December 2014), whichever came first. The diagnoses of HF were obtained from the Danish National Patient Registry, where nationwide data on ICD codes on all hospital admissions since 1977, and since 1995 data on outpatient and emergency room patients have been included. 10 The diagnosis of HF in the Danish National Patient Registry has been validated at several occasions with positive predictive values between 81% and 100%. 11, 12 Vital status was recorded from the Danish Civil Registry. system. 14 Covariate data were used to characterize the population in a descriptive manner. Data were linked on individual level between the complete Danish administrative registries by a unique 10 digit civil registration number, which is provided to all Danish citizens at birth or at achievement of permanent residency in Denmark.
Statistics
Baseline characteristics were described using proportions for categorical variables and medians/quartiles for continuous variables. The Wilcoxon two-sample test, the Chi-square test, and in case of numbers less than five the Fisher's exact test were used for comparison of baseline characteristics.
Incidence rates per 1000 patient-years for HF were calculated. Due to competing risk of death, the incidence of HF and the incidence of HF dependent on dose of epirubicin were evaluated using a cumulative incidence function accounting for death from all causes and Gray's test for equality was applied.
15 Kaplan-Meier estimates based on all-cause mortality were calculated and the log-rank test applied. Further, risk of HF was examined univariably in a Fine-Gray proportional hazards model with death as competing event with the Wald Chi-square test applied. The proportional hazards assumption was assessed graphically by a log(-log) S plot and by adding a time-dependent variable to the model, without determination of evidence against proportional hazards. Numbers needed to treat (NNT) with epirubicin to prevent one death as well as numbers needed to harm (NNH) to see one extra event of HF were calculated based on absolute risks.
Statistical analysis and data management were made by using the SAS statistical software package, version 9.4. (SAS Institute, Cary, NC, USA). A two-sided P-value of <0.05 was considered statistically significant. 
Ethics
Results
A total of 980 Danish patients were randomized in the DBCG 89D trial. Of these, 18 patients were afterwards treated outside the protocol and therefore excluded from this analysis. The number of patients allocated to the treatment regime containing epirubicin was 447, leaving 515 patients allocated to the non-epirubicin-containing regime. The reason for this imbalance in Denmark was because the original trial randomized patients across all participating countries with no stratification for country of enrolment. One patient with a diagnosis of HF prior to the diagnosis of breast cancer was excluded from the analysis (Figure 1) .
Baseline characteristics regarding age, tumour characteristics, and breast cancer treatment were balanced between the two treatment groups and are presented in Table 1 . At baseline, very few patients had any history of cardiovascular co-morbidity or use of cardiovascular medication ( Table 2 ). As presented in Figure 2A , the cumulative incidence of HF was significantly higher among patients treated with the epirubicin-containing regime compared with the non-epirubicin-containing regime (P < 0.01). The overall survival benefit in the epirubicin treatment group (P = 0.03) was preserved despite the increased incidence of HF as presented in Figure 2B . In the Fine-Gray proportional hazards model a hazard ratio of 3.00 (95% CI 1.39-6.49, P < 0.01) was found for HF associated with the epirubicin-containing regime.
Incidence and risk of heart failure
The NNH with epirubicin to see one extra case of HF was 29 and NNT with epirubicin to save one life was 18 after the median follow-up period of 16.9 years.
Dose dependency
The median dose of epirubicin in the study was 451.9 mg/m 2 (IQR 400.0-523.5). Figure 3 shows the cumulative incidence of HF according to distribution into two groups dependent on the dose of epirubicin below or equal to/above the median dose. There was no statistically significant difference in the incidence of HF between the low (n = 240) vs. high dose (n = 206) of epirubicin (P = 0.54).
Discussion
The present post hoc analysis of a randomized trial assessed the effect of epirubicin on long-term risk of HF after treatment of early breast cancer. The study yielded three main findings. First, the long-term incidence of HF after treatment for breast cancer is low. Second, the risk of HF is increased in patients treated with epirubicin compared with a non-anthracycline-based chemotherapy regime, and last, in the present study where the median dose was low (452 mg/m 2 ), there was no significant dose dependency. 
Incidence of heart failure
The low incidence of HF found in the study is comparable to a large meta-analysis of observational data on anthracycline-treated cancer patients, which reported an incidence of HF of 6.3% after 9 years of follow-up. 7 A similar low incidence was found in a Belgian trial comparing a non-epirubicin-containing regime with a low-dose (480 mg/m 2 ) vs. high-dose (800 mg/m 2 ) epirubicin regime. The study reported after 16 years of follow-up a proportion of HF of 5.5% in the high-dose regime. 16 This finding is, however, not unambiguous, since follow-up was not complete and the majority of HF cases also received left-sided radiotherapy, 17 which is a well-established risk factor for cardiac disease in general and particularly for ischaemic and valvular heart disease with the radiotherapy method used in the period of time of the trial. 18 In our study no correlation with HF and left-sided radiotherapy was found.
Our finding of a low incidence of HF was not surprising, since the women included in the DBCG 89D trial were young and had a very low burden of cardiovascular co-morbidity and minimal . consumption of any cardiovascular medication, indicating an a priori low risk of any cardiovascular events. However, large scale epidemiological registry data of unselected breast cancer patients also suggest that women with a diagnosis of breast cancer in general have low cardiovascular risk, and despite left-sided radiotherapy and chemotherapy have a lower mortality from cardiovascular causes than women from the background population.
18 This suggests that the present finding of a low incidence of long-term HF could be extrapolated to a more general clinical breast cancer population. On the other hand, the relative high mortality in this population compared to patients treated for breast cancer in recent years might conceal some long-term cases of HF.
Risk of heart failure
The increased long-term incidence of HF found in the epirubicin-treated group compared to a group that did not receive any anthracycline-based chemotherapy in the present study is to our knowledge the first to be reported in a randomized study, beside the finding from the Belgian trial, which reported a significantly higher proportion of HF in the high-dose epirubicin regime compared to the non-epirubicin-containing regime, but with the above-mentioned limitations.
17 At 10 years of follow-up in the original trial of this study, no additional occurrence of heart disease in the epirubicin-treated group was found, 2 which emphasizes the importance of the very long-term follow-up. Exactly how anthracyclines induce HF is unclear but likely multifactorial. Several mechanisms for short-term cardiotoxicity have been proposed including production of free radicals and mitochondrial dysfunction.
19 Whether this also is involved in long-term development of HF with a subclinical cardiotoxicity, which only years after treatment becomes apparent, is entirely speculative.
Taking overall survival benefit of adjuvant anthracyclines into account, it is important to emphasize, that HF is a rare but important side effect. This is stressed by the finding of a NNH (=29) to cause one extra case of HF almost twice as high as the NNT (=18) to save one life with treatment with epirubicin. Nonetheless, even with the significant improvements in treatment of chronic HF during the past decades, the diagnosis remains severe with a 5-year mortality of 53% for HF in general and a 1-year mortality rate of 7% and a 1-year hospitalization rate of 32% in chronic stable HF patients. 8, 9 Both the most recent US and European guidelines on HF highlight anthracycline-based chemotherapy as a risk factor for development of HF along with other risk factors such as hypertension and coronary artery disease. 20, 21 The data from the current study, however, suggest that the incidence rate of HF after epirubicin treatment is less than half of incidence rates of HF between 8.5 and 13.3 per 1000 patient-years, which have been reported in a population with hypertension. 22 Thus, although antracycline-related HF is clinically important, it is crucial to refine risk assessment to better identify those specific cancer patients with increased risk of developing HF, to avoid potential withdrawal of a lifesaving chemotherapy due to a minor cardiotoxic concern.
Dose dependency
A dose dependency between anthracycline-based chemotherapy and acute cardiotoxicity is well-established, 5, 23 but evidence that long-term risk of HF after anthracycline treatment is dose-dependent is lacking. In this study a weak insignificant signal of more diagnoses of HF among patients with a dose of epirubicin above the median dose was present, but the low number of events prevents any conclusion regarding this question.
Strengths and limitations
Some methodical strengths and limitations of the study should be acknowledged. The reported results are derived from a randomized trial and the complete follow-up due to linking of several nationwide registries by the unique civil registration number of all Danish citizens. The completion of the registries is ensured by an obligation by legislation to report to the registries.
10
With a positive predictive value of 81-100% for HF diagnosis in the Danish National Patient Registry in validation studies, 11, 12 the certainty of the HF cases found in the DBCG 89D trial is high. The limitation of the registry is, however, that only patients seen at a hospital are recorded, which will be patients with clinically significant symptoms. It is therefore possible that a number of patients with subclinical HF or very limited symptoms are not diagnosed and consequently not recorded in the Danish National Patient Registry. Another limitation of this study is the exclusion of 244 non-Danish participants, of whom we have no information about long-term incidence of HF.
Conclusion
In this post hoc analysis, patients randomized to epirubicin-based chemotherapy for breast cancer had an overall low risk of developing clinical HF, but the risk was increased compared to patients managed with a non-anthracycline-based regime.
. 
